MiniMed Group, Inc.

What they do

MiniMed develops, manufactures, and markets diabetes management solutions, primarily automated insulin delivery (AID) systems that integrate insulin pumps, CGM sensors, and proprietary dosing algorithms, and Smart MDI systems with smart insulin pens and CGMs. Its flagship AID system is the MiniMed 780G, with newer products including the MiniMed Flex pump and MiniMed Go Smart MDI. The company sells worldwide, distributing mostly through the U.S. DME channel and internationally through various channels.

Revenue drivers

• International AID systems and CGM sensors — FY2026 international net sales of $2.185 billion, up 20.6% as reported, driven by Simplera and Instinct CGM launches and capacity expansion.
• U.S. AID systems — FY2026 U.S. net sales of $917 million, up 1.5% as reported, with new sensor launches and pump demand, though early Flex clearance shifted some sales.
• Consumables and supplies — Recurring revenue from consumable infusion sets, reservoirs, and CGM sensors, with worldwide CGM attachment rate at 66% in FY2026.
• Smart MDI systems — Includes InPen smart insulin pens and CGM sensors; MiniMed Go Smart MDI launched in U.S. and EMEA, contributing to growth.

Recent performance

In Q4 FY2026 (ended April 24, 2026), net sales were $837 million, up 15.6% as reported and 8.7% organic year-over-year. Full-year FY2026 net sales were $3.102 billion, up 14.2% as reported and 8.0% organic. Net income was a loss of $333 million for FY2026, and operating cash flow was negative $197 million. Worldwide New Pumps Sold were 145,000 for the year, unchanged, while worldwide pump users reached 659,000. The company completed its IPO on March 9, 2026, after separating from Medtronic.

Strategy

MiniMed aims to accelerate growth through new product launches, including the MiniMed Flex pump and MiniMed Go Smart MDI, and by expanding CGM attach rates with sensors like Simplera and Instinct. It is extending its partnership with Abbott to commercialize dual glucose-ketone sensors for its smart dosing systems. The company is investing in its third-generation Vivera fully closed loop algorithm, with a U.S. pivotal study underway. It also continues to transition to standalone operations from Medtronic, with transitional manufacturing and services agreements in place.

Risks

• Intense competition — Competes with large and specialized players like Dexcom, Insulet, and Tandem in over 80 countries; rapid tech changes could make products obsolete.
• Supply chain and sole suppliers — Experienced supply interruptions for Simplera CGM and relies on sole suppliers for key components, which could disrupt sales.
• Pricing pressure — Pricing pressure in the market may compress margins, and reimbursement changes could affect demand.
• Transition and IPO costs — Operating as a standalone public company incurs incremental costs; results may not reflect future cost structure due to allocations from Medtronic.

Outlook

For fiscal year 2027 ending April 30, 2027, MiniMed expects organic revenue growth of approximately 10%, including a 1.0% to 1.5% benefit from an extra week. It guides to an adjusted EBITDA margin of approximately 16%. Management cites upcoming launches, such as MiniMed Flex in the U.S. and MiniMed 780G with Instinct in Europe, as drivers. The company also expects continued international momentum from CGM capacity expansion and new product introductions.